Genetic control of human androgen metabolism by the CYP17 and SRD5A2 genes

被引：0
|
作者：
Makridakis, N
Reichardt, J
Pike, M
Stanczyk, F
Yu, MM
Kolonel, L
Ross, R
Coetzee, G
Henderson, B
机构：
[1] USC, Sch Med, Los Angeles, CA USA
[2] Canc Res Ctr, Honolulu, HI USA
来源：
AMERICAN JOURNAL OF HUMAN GENETICS | 1997年 / 61卷 / 04期
关键词：
D O I：
暂无
中图分类号：
Q3 [遗传学];
学科分类号：
071007 ; 090102 ;
摘要：
1497
引用
收藏
页码：A257 / A257
页数：1
相关论文
共 50 条
  • [1] Association of prostate cancer risk and aggressiveness to androgen pathway genes:: SRD5A2, CYP17, and the AR
    Cicek, MS
    Conti, DV
    Curran, A
    Neville, PJ
    Paris, PL
    Casey, G
    Witte, JS
    PROSTATE, 2004, 59 (01): : 69 - 76
  • [2] The association between polymorphisms in the CYP17 and 5α-reductase (SRD5A2) genes and serum androgen concentrations in men
    Allen, NE
    Forrest, MS
    Key, TJ
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2001, 10 (03) : 185 - 189
  • [3] Genetic impact on prostate anatomical variability during ageing:: role of CYP17, SRD5A2 and androgen receptor genes polymorphisms
    Larre, Stephane
    Hamadeh, Hikmat
    Azzouzi, Abdel Rahmene
    Vallancien, Guy
    Cochand-Priollet, Beatrix
    Cancel-Tassin, Geraldine
    Cussenot, Olivier
    BJU INTERNATIONAL, 2007, 100 (03) : 679 - 684
  • [4] Hypospadias Risk and Polymorphism in SRD5A2 and CYP17 Genes: Case-Control Study Among Indian Children
    Samtani, Ratika
    Bajpai, Minu
    Vashisht, Kapil
    Ghosh, P. K.
    Saraswathy, K. N.
    JOURNAL OF UROLOGY, 2011, 185 (06): : 2334 - 2339
  • [5] Prostate cancer risk and polymorphism in 17 hydroxylase (CYP17) and steroid reductase (SRD5A2)
    Lunn, RM
    Bell, DA
    Mohler, JL
    Taylor, JA
    CARCINOGENESIS, 1999, 20 (09) : 1727 - 1731
  • [6] Association of Benign Prostate Hyperplasia with Polymorphisms in VDR, CYP17, and SRD5A2 Genes among Lebanese Men
    El Ezzi, Asmahan Ali
    Zaidan, Wissam Rateeb
    El-Saidi, Mohammed Ahmed
    Al-Ahmadieh, Nabil
    Mortenson, Jeffrey Benjamin
    Kuddus, Ruhul Haque
    ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2014, 15 (03) : 1255 - 1262
  • [7] Serum sex steroid hormone levels and polymorphisms of CYP17 and SRD5A2:: implication for prostate cancer risk
    Kakinuma, H
    Tsuchiya, N
    Habuchi, T
    Ohyama, C
    Matsuura, S
    Wang, L
    Nakamura, A
    Kato, T
    PROSTATE CANCER AND PROSTATIC DISEASES, 2004, 7 (04) : 333 - 337
  • [8] Serum sex steroid hormone levels and polymorphisms of CYP17 and SRD5A2: implication for prostate cancer risk
    H Kakinuma
    N Tsuchiya
    T Habuchi
    C Ohyama
    S Matsuura
    L Wang
    A Nakamura
    T Kato
    Prostate Cancer and Prostatic Diseases, 2004, 7 : 333 - 337
  • [9] The association of 5α-reductase II (SRD5A2) and 17 hydroxylase (CYP17) gene polymorphisms with prostate cancer patients in the Turkish population
    Onen, Ilke Hacer
    Ekmekci, Abdullah
    Eroglu, Muzaffer
    Polat, Fazli
    Biri, Hasan
    DNA AND CELL BIOLOGY, 2007, 26 (02) : 100 - 107
  • [10] Impact of genetic polymorphisms of 17-hydroxylase cytochrome P-450 (CYP17) and steroid 5α-reductase type II (SRD5A2) genes on prostate-cancer risk among the Japanese population
    Yamada, Y
    Watanabe, M
    Murata, M
    Yamanaka, M
    Kubota, Y
    Ito, H
    Katoh, T
    Kawamura, J
    Yatani, R
    Shiraishi, T
    INTERNATIONAL JOURNAL OF CANCER, 2001, 92 (05) : 683 - 686
12345